Business Wire

NY-IFF

Share
IFF Achieves Key 2020 Sustainability Goals

IFF (NYSE:IFF) today announced the achievement of key 2020 sustainability goals that were set at the launch of the Company’s sustainability program in 2010. During that time, IFF met and surpassed its original intensity-based targets for three environmental goals, resulting in a reduction in its greenhouse gas (GHG) emissions, water withdrawal and hazardous waste generation per metric ton of production by -42.6%, -67.1% and -41% below 2010 levels, respectively. IFF has also achieved its 2020 goal to have 100% of the palm oil used in its products be certified according to the Roundtable on Sustainable Palm Oil (RSPO) Mass Balance Supply Chain Model.

These and other milestones are captured in its latest Sustainability Report, “For a Better World,” which is published today. The title references the Company’s purpose – Applying science and creativity for a better world – a clear and bold aspiration that inspires everyone at IFF to push past traditional boundaries and to be a force for a better and more sustainable future.

Andreas Fibig, IFF Chairman and CEO, said: “Although 2020 was a year unlike any we could have predicted, I am proud to say that IFF rose to the challenges we faced and remained steadfast in our commitments to people and planet – further strengthening our sustainability leadership position. As pleased as we are with our results, the solemnity of the urgent challenges that remain – from the climate emergency and nature loss to mounting inequality – compels us to do more, to do better. As we work toward a better world with the continued support of our employees, customers, suppliers and other partners, we look forward to building on our successes in 2020 and achieving even more ambitious environmental, social and governance (ESG) targets in the future.”

In addition to highlighting progress against IFF’s 2020 environmental goals, the report also covers the Company’s achievements throughout the business in leveraging sustainable practices within its global footprint. For example:

  • Externally recognized for sustainability leadership, including being named to the Dow Jones Sustainability Indices, FTSE4Good Index Series, Euronext Vigeo World 120 Index and CDP A list, as well as receiving the EcoVadis platinum sustainability rating
  • Continued its commitment to climate action by advancing on its Science Based Target to reduce absolute GHG emissions by 19.7% since 2015; powering 52% of its operations’ electricity requirements with renewable energy; and reporting for the first time in alignment with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD)
  • Expanded safety culture and training, resulting in a reduction in its lost time incident rate of 46% from the prior year
  • Launched industry-leading blockchain technology as a tool for ensuring ingredient traceability in the vanilla supply chain in Madagascar
  • Further embedded its commitment to circular design across its business, including by launching the Upcycled Extracts Collection, an ingredients portfolio made from several types of side-streams from its own processing that would otherwise be discarded
  • Strengthened its commitment to diversity, equity & inclusion and was the first company to earn Economic Dividend for Gender Equality (EDGE) Move level certification globally

Dr. Greg Yep, IFF’s Chief Research & Development, Global Integrated Solutions and Sustainability Officer, said, “Looking back over ten years of sustainability at IFF, we are thrilled with what we have been able to achieve. Following the merger with DuPont Nutrition & Biosciences, the decade ahead not only marks the next phase of IFF’s sustainability journey, but also represents a pivotal window of opportunity. By focusing on sustainable innovation, circular design and integrated solutions, we look forward to leveraging our newly expanded capabilities to help address the world’s greatest sustainable development challenges.”

To read IFF’s 2020 Sustainability Report, visit iff.com/responsibilities and use #DoMoreGoodxIFF to follow the conversation on its social channels.

Webcast

A live webcast to discuss the Company’s 2020 sustainability results and 2021 outlook will be held on May 20, 2021 at 9:00 a.m. ET. Mr. Fibig and Dr. Yep will be joined by Chief Investor Relations & Communications Officer Michael DeVeau; and Vice President, Global Sustainability & EHS Kip Cleverley, who will share updates on IFF’s key ESG metrics, goals and sustainability strategy. The webcast and accompanying slide presentation may be accessed on the Company’s Investor Relations website at ir.iff.com .

Investors and analysts are invited to participate by phone by calling 1-866-342-8591 from the United States and 1-203-518-9713 from other locations. The access code for the conference call is IFF0520 and a listen-only webcast will be available at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available on the Company’s website approximately one hour after the event.

Welcome to IFF

At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release

Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release

52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society

Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release

- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and

Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release

The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p

Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release

‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye